Objective To specify the diagnostic accuracy of low-field MRI on meniscal tears. Methods Meniscal lesions were examined by using 0.2 T MRI and checked arthroscopically in 171 cases. The results were recorded and compared. Results From the calculation of the arthroscopic findings and the results by MRI, we obtained the diagnostic accuracy rate of 95.91% for both the medial and lateral menisci, sensitivity of 95.60% for the medial menisci and 96.47% for the lateral menisci, and specificity of 96.25% for the medial menisci and 95.35% for the lateral menisci. Conclusions The low-field MRI can bring about high diagnostic accuracy for meniscal tears and has a good price-performance ratio.

［摘要］ 目的：探讨穿膜蛋白125（transmembrane protein125，TMEM125）在肺腺癌组织与A549 细胞中的表达，以及影响细胞 的增殖和侵袭能力的分子机制。方法：从癌症基因组图谱（the cancer genome atlas，TCGA）数据库收集肺腺癌数据包，下载临床 信息及基因表达谱数据。分析TMEM125 在肺腺癌组织中的表达及其与患者总生存期的相关性。构建TMEM125 过表达A549 细胞株，以CCK-8 法、细胞划痕实验检测TMEM125 过表达对肿瘤细胞的增殖和迁移能力的影响；流式细胞术检测TMEM125 过 表达对A549 细胞的细胞周期和凋亡的影响。WB检测TMEM125 过表达对下游NF-κB信号通路、凋亡蛋白的影响；免疫共沉淀 法（co-immunoprecipitation，Co-IP）检测TMEM125 与NF- κB 抑制因子结合Ras 样2（NF- κB inhibitor interacting Ras-like 2， NKIRAS2）的相互作用。利用TNFα（10 ng/ml）处理TMEM125 过表达A549 细胞，CKK-8、流式细胞术及WB检测其对细胞增殖、 凋亡以及NF-κB信号通路相关蛋白表达的影响。去甲基化试剂地西他滨处理A549 细胞，qPCR和WB检测TMEM125 基因和蛋 白的表达。结果：TMEM125 mRNA在肺腺癌组织中表达水平显著低于正常组织（P<0.001），启动子甲基化水平显著高于正常组 织（P<0.001），并且低、中表达患者总生存期显著低于高表达患者（P<0.001）。过表达TMEM125 抑制了A549 细胞的增殖和迁移 （P<0.01），增加细胞G2/M 期，促进细胞凋亡（P<0.01）；过表达TMEM125 与NKIRAS2 相互作用，显著抑制NF- κB 的活性 （P<0.01）；地西他滨处理A549 细胞可促进TMEM125 表达并且抑制细胞增殖（P<0.01）。结论：启动子高甲基化水平降低了 TMEM125 基因表达，导致其抑制NF-κB活性功能和抑制细胞增殖的作用下降，并且降低了细胞对地西他滨的敏感性。

Periodontitis is the inflammation of periodontal tissue caused by dental plaque, which absorbs the alveolar bone and cementum. The immune response triggered by CD4+T cells is the key factor for the aggravation of periodontitis. The activation of dendritic cells and the receptor activator of the NF-κB ligand (RANKL) pathway is an important link in the alveolar bone resorption of periodontal tissue. Pro-inflammatory factors such as interferon-γ (IFN-γ), tumor necrosis factor (TNF-α) and interleukin-1β (IL-1β) also play important roles in the development of periodontitis. Interleukin-37(IL-37), which is a newly discovered cytokine in the IL-1 family, has five shear variants from a to e, among which the clover β-structure encoded by exon 4 plays an important role in the binding of cytokines and the corresponding receptors. IL-37 has strong anti-inflammatory and inhibition of autoimmunity, can enter the nucleus with the help of caspase-1 and bind with Smad proteins to regulate the transcription of pro-inflammatory genes. Extracellular IL-37 can bind to IL-18 binding protein and inhibit the production of pro-inflammatory factors. IL-37 can inhibit the progression of periodontitis by inhibiting the RANKL signaling pathway, inhibiting the proliferation and differentiation of dendritic cells and CD4+T cells, binding to Smad proteins, and releasing pro-inflammatory factors such as IFN-γ and TNF-α. The IL-37 concentration in periodontal tissue can indicate the progression of periodontitis. Few studies have described the interaction between the anti-inflammatory factor IL-37 and periodontitis. Thus, in this paper, the structure and function of IL-37 and the related factors between IL-37 and periodontitis will be reviewed.

Objective To study the regulatory effect and molecular mechanism of juglone on apoptosis of cervical cancer Hela cells. Methods Cervical cancer Hela cells were cultured and treated with different dosages of juglone (10, 20, and 40 μmol/L, respectively) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (10, 20, and 40 μmol/L, respectively). Then cellular proliferative activity and the expression of JNK/c-Jun pathway molecule and apoptotic molecule in the cells were detected. Results After 6, 12, 18 and 24 h of treatment, the value for proliferative activity of cells treated with juglone was significantly lower than that of control group (P < 0.05), and the anti-proliferative effect was more significant as the treatment period and juglone dosage increased (P < 0.05). The protein expressions of Bax, CytC, Fas, FasL, Caspase-3, p-JNK and p-c-Jun in cells treated with juglone were significantly higher than those of control group (P < 0.05), and the protein expressions of Bax, CytC, Fas, FasL, Caspase-3, p-JNK and p-c-Jun increased more remarkably as the juglone dosage increased (P < 0.05). In cells treated with 40 μmol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 μmol/L juglone (P < 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P < 0.05). Conclusion Juglone can increase the expression of apoptotic molecules in mitochondrial pathway and death receptor pathway by activating JNK/c-Jun pathway, thus inducing apoptosis of cervical cancer cells.

Objective To study the expression of E6 and E7 mRNA in high-risk human papillomavirus (HPV) HPV-18 and the relationship between the expression of invasive gene and cervical carcinoma. Methods A total of 119 patients with cervical cancer, cervical erosion and cervical HPV infection who were diagnosed in our hospital were selected and randomly divided into two groups: cervical cancer group (n = 58) and non-cancerous group (n = 61). Another 60 patients with uterine leiomyoma were selected as normal control group. Detection of HPV18 E6, E7 mRNA expression and invasion, migration, proliferation inhibition genes, epithelial mesenchymal transition genes and proliferation related protein content. Results The relative expression of E6 and E7 HPV-18 in cervical cancer group was significant higher than that in non-cancerous group and control group (mRNA) (P < 0.05). The content of TRAF6 and c-FLIP in invasive cervical cancer group was significantly higher than that in non-cancerous group and control group (P < 0.05). The mRNA content of CD44v6 and MMP-9 in cervical cancer group was significantly higher than that in non-cancerous group and control group (P < 0.05). The content of DEC-1, IKK16, MBP-1 in cervical cancer group was significant lower than that in non-cancerous group and control group (P < 0.05). The mRNA content of beta -catenin and Vimentin in cervical cancer group was significantly lower than that in non cancerous group and control group (P < 0.05). The proliferation related protein E2F1 of cervical cancer group was significantly lower than that of non-cancerous group and control group, Bmi-1 content was significantly higher than non-cancerous group and control group (P < 0.05). Conclusions The expression of the detection of cervical cancer in high-risk human papilloma virus HPV-18 E6 and E7 mRNA, and the invasion, migration, proliferation inhibition gene, epithelial mesenchymal transition and proliferation related gene protein content, HPV expression rate of mRNA increased with the development of cervical cancer, the expression is also enhanced. The expression has a certain correlation between the level and development of cervical cancer. Through the above indicators, the development of cervical cancer monitoring and treatment to provide important clinical guidance.

OBJECTIVE: To investigate the imaging characteristics of F-FDG positron emission computed tomography (F-FDG PET/CT) in multiple myeloma (MM) patients and to analyze its application value in MM and bone metastases. METHODS: A retrospective analysis was made on MM patients (n=72) and bone metastases patients (n=50) admitted to Hainan Western Central Hospital from January 2017 to March 2019. All patients underwent F-FDG PET/CT examination. The distribution of lesions, bone destruction, maximum standardized uptake (SUV) and metabolic homogeneity were analyzed in both groups. RESULTS: More than 80% of MM and bone metastases involved thoracic bone, spine and pelvis, followed by limbs. MM was more common in the lesions of thoracic bone and skull than those in bone metastases, the difference was statistically significant (P＜0.05). The majority of MM patients presented osteolytic bone destruction (97.2%), mostly showing "insect-like phagocytic pattern", so the bone showed dilated changes, and osteogenic changes were rarely seen (2.8%). Osteolytic bone destruction accounted for 74.0% in patients with bone metastatic tumor, presenting "focal" appearance more often, and osteogenic changes accounted for 26.0%. Osteolytic bone destruction in patients with MM was significantly higher than that in patients with bone metastases（χ=14.757，P＜0.05）. The SUV of MM (4.25±2.16)was significantly lower than that of bone metastases (7.84±3.25) (t=6.830, P＜0.05). Diffuse mild uptake of F-FDG was more common in patients with MM, and heterogeneous high uptake of F-FDG was more common in patients with bone metastasis, the difference was statistically significant (P＜0.05). CONCLUSION F-FDG PET/CT examination is helpful to acquire the imaging features of bone structure and metabolic changes, and shows an important clinical value in the differential diagnosis of MM and bone metastases.
Fluorodeoxyglucose F18 ; Humans ; Multiple Myeloma ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Radiopharmaceuticals ; Retrospective Studies ; Tomography, X-Ray Computed

OBJECTIVE: To investigate the prognostic value of metabolic parameters of METHODS: The clinical data of 58 patients with DLBCL who were examined by RESULTS: The SUV CONCLUSION MTV and TLG are independent risk factors for OS and PFS in patients with DLBCL, which may be valuable for prognosis of patients with DLBCL.
Fluorodeoxyglucose F18 ; Humans ; Lymphoma, Large B-Cell, Diffuse ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Prognosis ; Retrospective Studies

OBJECTIVE: To analyze the expression level of the serum soluble E cadherin (SE-CAD) and Matriptase and its clinical significance for evaluation of the disease condtions and prognosis in patients with acute myeloid leukemia (AML). METHODS: One hundred and ten patients diagnosed as AML in our hospital were divided into 3 groups: newly diagnosed group (38 cases), remission group (40 cases) and recurrence group (32 cases). The expression levels of serum matriptase were detected by Western blot, and the expression levels of serum SE-CAD were detected by ELISA. The serum levels of serum SE-CAD and matriptase among 3 groups were compared. Followin-up for one year, according to the outcome of patients, all the patients were divided into 2 groups: the survival group and death group. The serum levels of SE-CAD and Matriptase were compared between 2 groups. The correlation of serum levels of SE-CAD and matriptase with the survival of AML patients was analyzed by multivariate Logistic analysis. The evaluation value of the serum levels of SE-CAD and matriptase for the prognosis of the patients with AML were analyzed by receiver operating characteristic curves (ROC). RESULTS: The serum levels of SE-CAD and matriptase were siginificantly different among 3 groups (P＜0.05). The serum levels of SE-CAD and matriptase in remission group were lowest (P＜0.05), and the serum levels of SE-CAD and matriptase were not different between newly diagnoses and recurrence groups (P＞0.05). Multivariate Logistic analysis showed that the serum levels of SE-CAD and matriptase were independent risk factors for the prognosis of AML patients (OR=3.157, P＜0.05, OR=2.426, P＜0.05). By follow-up for 1 year, the serum expression levels of SE-CAD and Matriptase in survival group were lower than that in death group. ROC curve showed that when the cut-off value of matriptase level was 0.73 and SE-CAD level was 3.42 ng/ml, the AUC of predictions for the poor prognosis in AML patients was 0.849 (P＜0.05), the sensitivity was 85.6% (95%CI: 0.810~0.924) and specificity was 89.6% (95%CI: 0.849~0.941). CONCLUSION The serum levels of SE-CAD and matriptase can perfectly evaluate the condition and short-term prognosis of the patients with AML.
Cadherins ; Humans ; Leukemia, Myeloid, Acute ; Prognosis ; Serine Endopeptidases

OBJECTIVE: To investigate the incidence, clinical features of U2AF1 gene mutation in patients with acute myeloid leukemia(AML) and its effect of prognosis. METHODS: A total of 161 patients with AML were enrolled. The second-generation sequencing method was used to detect U2AF1 gene mutation, and the relationship between U2AF1 mutation and clinical features, prognosis was analyzed. RESULTS: The mutation rate of U2AF1 gene in 161 AML patients was 3.73%. The counts of peripheral blood leukocytes and platelets in the U2AF1 gene mutation group were lower than those in the wild type group. The complete response rate of U2AF1 gene mutation group was 66.67%, while that in wild type group was 55.48%, which shows no significant difference between the two groups (P=0.70). The median EFS of wild type group and the mutant group was not reached and reached to 133 days, respectively (P=0.03), while the medium OS in two groups was not reached and reached to 210 days (P=0.01). CONCLUSION The AML patients with U2AF1 mutation positive have a poor prognosis as compared with the wild type group, which may be a poor prognostic factor for acute myeloid leukemia.